The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Okazaki A, Kita K

Venlafaxine-induced interstitial lung disease with COVID-19 pandemic-related depression.

Clinical case reports. 2022;10(6):e05941

Borderías Clau L, Marigil Gómez MA, Val Adán P, Marcén Letosa M, Biescas López R, Garrapiz López FJ

[Hypersensitivity pneumonitis due to venlafaxine].

Archivos de bronconeumologia. 2008;44(10):571-3

Vázquez MJ, Carretero Quevedo B

Pneumonitis related to venlafaxine.

Psychosomatics. 2008;49(1):84-5

Turner RC, Nelson JE, Roberts BT, Gillam DM

Venlafaxine-associated interstitial pneumonitis.

Pharmacotherapy. 2005;25(4):626-9

Drent M, Singh S, Gorgels AP, Hansell DM, Bekers O, Nicholson AG, van Suylen RJ, du Bois RM

Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine.

American journal of respiratory and critical care medicine. 2003;167(7):958-61